Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.
Laurence Albigès(Université Paris-Saclay), Toni K. Choueiri(Harvard University), Charles Dariane(Sorbonne Université), Bernard Escudier(Institut Gustave Roussy), Wanling Xie(Dana-Farber Cancer Institute), André P. Fay(Hospital São Lucas da PUCRS), Guillermo de Velasco(Dana-Farber Cancer Institute), David F. McDermott(Beth Israel Deaconess Medical Center), Daniel Yick Chin Heng(University of Calgary), Renee Lester(Baker Hughes (Canada))
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k